Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Von Eschenbach still in limbo

Executive Summary

Senate Finance Committee Chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach to be permanent FDA commissioner Nov. 16. The senator objects to von Eschenbach's "failure to comply with the committee's subpoenas over the past six months." In May, Grassley requested a briefing by senior FDA staff, a meeting with a line investigator and access to study data related to Sanofi-Aventis' Ketek (telithromycin) after allegations of data integrity problems in the antibiotic's NDA. Grassley is the third Senator to place a hold on the nomination, following Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.). Senate Health Committee Chair Mike Enzi (R-Wyo.) has vowed to work to lift the holds to allow for confirmation before Congress adjourns (1"The Pink Sheet" Sept. 25, 2006, p. 4)...

You may also be interested in...



Von Eschenbach Receiving HELP With GOP Nomination Hurdles

Senate Health, Education, Labor & Pensions committee members are working to end Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post

What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel